Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 33

1.

Stage IV Colorectal Cancer Patients with High Risk Mutation Profiles Survived 16 Months Longer with Individualized Therapies.

Hendricks A, Amallraja A, Meißner T, Forster P, Rosenstiel P, Burmeister G, Schafmayer C, Franke A, Hinz S, Forster M, Williams CB.

Cancers (Basel). 2020 Feb 8;12(2). pii: E393. doi: 10.3390/cancers12020393.

2.

Dasatinib attenuates overexpression of Src signaling induced by the combination treatment of veliparib plus carboplatin in triple-negative breast cancer.

Sun Y, Lin X, Aske JC, Ye P, Williams C, Abramovitz M, Leyland-Jones BR.

Cancer Chemother Pharmacol. 2019 Dec;84(6):1241-1256. doi: 10.1007/s00280-019-03962-8. Epub 2019 Sep 20.

PMID:
31541266
3.

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study.

Sicklick JK, Kato S, Okamura R, Schwaederle M, Hahn ME, Williams CB, De P, Krie A, Piccioni DE, Miller VA, Ross JS, Benson A, Webster J, Stephens PJ, Lee JJ, Fanta PT, Lippman SM, Leyland-Jones B, Kurzrock R.

Nat Med. 2019 May;25(5):744-750. doi: 10.1038/s41591-019-0407-5. Epub 2019 Apr 22.

4.

RET rearrangements are actionable alterations in breast cancer.

Paratala BS, Chung JH, Williams CB, Yilmazel B, Petrosky W, Williams K, Schrock AB, Gay LM, Lee E, Dolfi SC, Pham K, Lin S, Yao M, Kulkarni A, DiClemente F, Liu C, Rodriguez-Rodriguez L, Ganesan S, Ross JS, Ali SM, Leyland-Jones B, Hirshfield KM.

Nat Commun. 2018 Nov 16;9(1):4821. doi: 10.1038/s41467-018-07341-4.

5.

RNA based individualized drug selection in breast cancer patients without patient-matched normal tissue.

Forster M, Mark A, Egberts F, Rosati E, Rodriguez E, Stanulla M, Bauerschlag D, Schem C, Maass N, Amallraja A, Murphy KK, Prouse BR, Sulaiman RA, Young BM, Mathiak M, Hemmrich-Stanisak G, Ellinghaus D, Weidinger S, Rosenstiel P, Arnold N, Leyland-Jones B, Williams CB, Franke A, Meißner T.

Oncotarget. 2018 Aug 17;9(64):32362-32372. doi: 10.18632/oncotarget.25981. eCollection 2018 Aug 17.

6.

Triple Fluorescence staining to Evaluate Mechanism-based Apoptosis following Chemotherapeutic and Targeted Anti-cancer Drugs in Live Tumor Cells.

De P, Carlson JH, Leyland-Jones B, Williams C, Dey N.

Sci Rep. 2018 Sep 4;8(1):13192. doi: 10.1038/s41598-018-31575-3.

7.

Intermittent, extended access to preferred food leads to escalated food reinforcement and cyclic whole-body metabolism in rats: Sex differences and individual vulnerability.

Spierling SR, Kreisler AD, Williams CA, Fang SY, Pucci SN, Kines KT, Zorrilla EP.

Physiol Behav. 2018 Aug 1;192:3-16. doi: 10.1016/j.physbeh.2018.04.001. Epub 2018 Apr 11.

8.

Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer.

Bubalo JS, Herrington JD, Takemoto M, Willman P, Edwards MS, Williams C, Fisher A, Palumbo A, Chen E, Blanke C, Lopez CD.

Support Care Cancer. 2018 Apr;26(4):1273-1279. doi: 10.1007/s00520-017-3950-y. Epub 2017 Oct 31.

PMID:
29090385
9.

Promise of Precision Medicine in Cancers: Lessons Learned.

Dey N, Williams C, Leyland-Jones B, De P.

S D Med. 2017 Nov;70(11):486-490. No abstract available.

PMID:
29088519
10.

Utilizing Tumor and Plasma Liquid Biopsy in Treatment Decision Making for an Estrogen Receptor-Positive Advanced Breast Cancer Patient.

Xu B, Krie A, De P, Williams C, Elsey R, Klein J, Leyland-Jones B.

Cureus. 2017 Jun 29;9(6):e1408. doi: 10.7759/cureus.1408.

11.

Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events.

Meißner T, Mark A, Williams C, Berdel WE, Wiebe S, Kerkhoff A, Wardelmann E, Gaiser T, Müller-Tidow C, Rosenstiel P, Arnold N, Leyland-Jones B, Franke A, Stanulla M, Forster M.

Cold Spring Harb Mol Case Stud. 2017 Jul 5;3(4). pii: a001677. doi: 10.1101/mcs.a001677. Print 2017 Jul.

12.

Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary.

Kato S, Krishnamurthy N, Banks KC, De P, Williams K, Williams C, Leyland-Jones B, Lippman SM, Lanman RB, Kurzrock R.

Cancer Res. 2017 Aug 15;77(16):4238-4246. doi: 10.1158/0008-5472.CAN-17-0628. Epub 2017 Jun 22.

13.

Down's Syndrome and Triple Negative Breast Cancer: A Rare Occurrence of Distinctive Clinical Relationship.

Dey N, Krie A, Klein J, Williams K, McMillan A, Elsey R, Sun Y, Williams C, De P, Leyland-Jones B.

Int J Mol Sci. 2017 Jun 7;18(6). pii: E1218. doi: 10.3390/ijms18061218.

14.

Mutation matters in precision medicine: A future to believe in.

Dey N, Williams C, Leyland-Jones B, De P.

Cancer Treat Rev. 2017 Apr;55:136-149. doi: 10.1016/j.ctrv.2017.03.002. Epub 2017 Mar 16. Review.

PMID:
28371665
15.

Identifying biomarkers to select patients with early breast cancer suitable for extended adjuvant endocrine therapy.

Abramovitz M, Krie A, Dey N, De P, Williams C, Leyland-Jones B.

Curr Opin Oncol. 2016 Nov;28(6):461-468. Review.

PMID:
27606693
16.

Dual Blockade of HER-2 Provides a Greater Magnitude of Benefit in Patients With Hormone-Negative Versus Hormone-Positive Breast Cancer.

Abramovitz M, Williams C, Loibl S, Leyland-Jones B.

Clin Breast Cancer. 2016 Dec;16(6):444-455. doi: 10.1016/j.clbc.2016.06.004. Epub 2016 Jun 14. Review.

PMID:
27435628
17.

Single Gene Prognostic Biomarkers in Ovarian Cancer: A Meta-Analysis.

Willis S, Villalobos VM, Gevaert O, Abramovitz M, Williams C, Sikic BI, Leyland-Jones B.

PLoS One. 2016 Feb 17;11(2):e0149183. doi: 10.1371/journal.pone.0149183. eCollection 2016.

18.

A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy.

Williams CB, McMahon C, Ali SM, Abramovitz M, Williams KA, Klein J, McKean H, Yelensky R, George TJ Jr, Elvin JA, Soman S, Lipson D, Chmielecki J, Morosini D, Miller VA, Stephens PJ, Ross JS, Leyland-Jones B.

Onco Targets Ther. 2015 Dec 1;8:3561-4. doi: 10.2147/OTT.S90766. eCollection 2015.

19.

A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK.

Dey N, Williams C, Leyland-Jones B, De P.

Am J Transl Res. 2015 Apr 15;7(4):733-50. eCollection 2015.

20.

Understanding the exercise habits of residents and attending physicians: a mixed methodology study.

Williams AS, Williams CD, Cronk NJ, Kruse RL, Ringdahl EN, Koopman RJ.

Fam Med. 2015 Feb;47(2):118-23.

Supplemental Content

Loading ...
Support Center